Mercaptopurin-Medice (Mercaptopurine)

Mercaptopurine is converted inside cells to thioinosine monophosphate, which blocks the synthesis of purine nucleotides. This disruption prevents DNA and RNA formation, leading to cytotoxic effects on fast‑growing cells, including malignant leukemic cells and activated immune cells.

The dose of Mercaptopurin-Medice is individualized by the prescribing clinician based on the patient’s diagnosis, age, weight, renal and hepatic function, and treatment response. Exact dosing regimens should be obtained from the treating physician.

Safety data for mercaptopurine in pregnancy and lactation are limited, and the drug is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk, and breastfeeding decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mercaptopurin-Medice is a thiopurine similar to azathioprine but is administered as the active metabolite itself, allowing more direct dosing. Compared with azathioprine, it may have a faster onset of action but also carries a higher risk of myelosuppression, requiring closer laboratory monitoring.

Mercaptopurin-Medice should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, heat and direct sunlight to maintain stability.

The medication is taken orally, usually as a tablet, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

The most serious risks include severe bone‑marrow suppression leading to infections, anemia or bleeding; hepatotoxicity; pancreatitis; and rare but life‑threatening hypersensitivity reactions. Patients should be monitored regularly for blood counts and liver function.

Mercaptopurin-Medice is contraindicated in individuals with known hypersensitivity to mercaptopurine or any thiopurine, in patients with severe hepatic impairment, and in those with active, uncontrolled infections. Caution is also advised for patients with pre‑existing bone‑marrow disorders.